Bills Search Results

Search all bills

Keyword(s)

Help icon Using the Bill Introduced date fields will allow you to search bills by the date they were introduced into Parliament.
Clicking the 'Bill Introduced (From)' and 'Bill Introduced (To)' fields displays a calendar.
Alternatively select date by typing into these fields in the format 'dd/mm/yyyy'.

Help icon Using the Bill Progress date fields will allow you to search bills by the dates they progressed through Parliament.
Clicking the 'Bill Progress (From)' and 'Bill Progress (To)' fields displays a calendar.
Alternatively select date by typing into these fields in the format 'dd/mm/yyyy'.

Status
Current Bills
Previous Bills
Type

TOTAL RESULTS: 741

Sort

  • Therapeutic Goods Amendment (Repeal of Ministerial responsibility for approval of RU486) Bill 2005 [2006]

    Track (What's this?)

    Date
    08 Dec 2005 
    Chamber
    Senate 
    Status
    Act 
    Sponsor
    NASH, Sen Fiona
    TROETH, Sen Judith
    ALLISON, Lyn
    MOORE, Sen Claire 
    Summary
    Amends the
    Therapeutic Goods Act 1989
    to transfer the responsibility for regulatory approval of RU486 from the Minister for Health and Ageing to the Therapeutic Goods Administration. 

    Bill | Explanatory Memorandum

  • Therapeutic Goods Amendment (Poisons Standard) Bill 2008

    Track (What's this?)

    Date
    14 Feb 2008 
    Chamber
    House of Representatives 
    Status
    Act 
    Portfolio
    Health and Ageing 
    Summary
    Amends the
    Therapeutic Goods Act 1989
    to address legal consequences arising from the Federal Court decision in
    Roche Products v National Drugs and Poisons Schedule Committee
    [2007] FCA 1352 (30 August 2007) by: providing that the Poisons Standard and its amendments are legislative instruments for the purposes of the
    Legislative Instruments Act 2003
    ; retrospectively reinstating certain amendments made to the Standard before the Roche decision; exempting the Standard from section 42 of the
    Legislative Instruments Act 2003
    relating to disallowance; and providing for ‘just terms’ compensation in the event that these measures could result in any acquisition of property. 

    Bill | Explanatory Memorandum

  • Therapeutic Goods Amendment (Pharmaceutical Transparency) Bill 2013

    Track (What's this?)

    Date
    28 Feb 2013 
    Chamber
    Senate 
    Status
    Not Proceeding 
    Sponsor
    DI NATALE, Sen Richard 
    Summary
    Amends the
    Therapeutic Goods Act 1989
    to: create offences related to the provision of payments, services or certain other inducements to medical practitioners by pharmaceutical companies; and provide for: penalties for making such inducements; and reporting requirements. 

    Bill | Explanatory Memorandum

  • Therapeutic Goods Amendment (Medical Devices) Bill 2002

    Track (What's this?)

    Date
    14 Feb 2002 
    Chamber
    House of Representatives 
    Status
    Act 
    Portfolio
    Health and Ageing 
    Summary
    Introduced with the Therapeutic Goods (Charges) Amendment Bill 2002, the bill amends the
    Therapeutic Goods Act 1989
    to introduce a medical device regulatory system, including a new electronic application lodgment system for inclusion of medical devices on the Australian Register of Therapeutic Goods; and provides transitional arrangements. 

    Bill | Explanatory Memorandum

  • Therapeutic Goods Amendment (Medical Devices) Bill 2001

    Track (What's this?)

    Date
    29 Mar 2001 
    Chamber
    House of Representatives 
    Status
    Not Proceeding 
    Portfolio
    Health and Aged Care Portfolio 

    Bill | Explanatory Memorandum

  • Therapeutic Goods Amendment (Medical Devices and Other Measures) Bill 2008 [2009]

    Track (What's this?)

    Date
    03 Dec 2008 
    Chamber
    Senate 
    Status
    Act 
    Portfolio
    Health and Ageing 
    Summary
    Amends the
    Therapeutic Goods Act 1989
    to: exempt medical devices from the operation of the Act to enable goods to be stockpiled for use in a health emergency and remove the requirement that such exemptions are disallowable instruments; adjust the test of whether a person is a ‘fit and proper person’ to hold a manufacturing licence or a medical device conformity assessment certificate; adopt the European Pharmacopoeia and United States Pharmacopoeia as additional default standards; enable public access to information held by the Therapeutic Goods Administration; ensure controls over restricted and prohibited representations apply to advertisements in all media; and align penalties with current policy formulations. 

    Bill | Explanatory Memorandum

  • Therapeutic Goods Amendment (2022 Measures No. 1) Bill 2022

    Track (What's this?)

    Date
    01 Dec 2022 
    Chamber
    House of Representatives 
    Status
    Act 
    Portfolio
    Health and Aged Care 
    Summary
    Amends the
    Therapeutic Goods Act 1989
    to: require mandatory reporting of adverse events involving medical devices; provide a marketing approval pathway for biologicals that are for export only; remove merits review rights for a decision by the secretary to require a person to provide information or documents under the Act; enable the secretary to extend the period for a person to pay the amount stated in an infringement notice, and require a person to provide information or documents that are relevant to a contravention of the Act; extend the period for which seized goods can be held; provide that therapeutic goods advertising is excluded from advertising restrictions for certain health professionals or to persons purchasing goods on behalf of governments, registered charities or health facilities; enable the secretary to withdraw approval for the use of a restricted representation in an advertisement about therapeutic goods; enable the secretary to approve the importation or supply of substitute overseas prescription medicine that has been previously approved within Australia; provide that the secretary is not required to observe any requirements of the natural justice hearing rule when releasing therapeutic goods information; provide that sponsors of reportable medicines that are in shortage must provide updated information to the secretary; and make technical amendments. 

    Bill | Explanatory Memorandum

  • Therapeutic Goods Amendment (2020 Measures No. 2) Bill 2020

    Track (What's this?)

    Date
    09 Dec 2020 
    Chamber
    House of Representatives 
    Status
    Act 
    Portfolio
    Health 
    Summary
    Amends the
    Therapeutic Goods Act 1989
    to: enable pharmacists to substitute a different medicine for one that has been prescribed where there is a serious scarcity of the prescribed medicine; allow the making of regulations to establish a unique device identification database for the traceability and monitoring of medical devices in Australia; enable authorised employees in the Department of Health to obtain and possess prescription medicines, or unapproved therapeutic goods, without contravening state and territory laws; allow the making of regulations to prohibit the import, export, supply or manufacture of therapeutic goods that are prohibited under international agreements; ensure the timely availability of COVID-19 vaccines by enabling the secretary to consent to the importation and supply of registered or listed therapeutic goods that do not have their registration or listing number on the label; make amendments in relation to the operation of the data protection scheme for assessed listed medicines; and make minor and technical amendments. 

    Bill | Explanatory Memorandum

  • Therapeutic Goods Amendment (2020 Measures No. 1) Bill 2020

    Track (What's this?)

    Date
    04 Mar 2020 
    Chamber
    House of Representatives 
    Status
    Act 
    Portfolio
    Health 
    Summary
    Amends the:
    Therapeutic Goods Act 1989
    to: align certain device-related definitions with the equivalent definition in the European Union; enable the secretary to provide early scientific advice to a sponsor about the safety, quality or efficacy of a registrable medicine; enable a clinical trial sponsor to request variations to approved clinical trials; introduce a new preliminary assessment procedure for applications for new ingredients for listed and assessed listed medicines; remove a limitation on the circumstances in which medical practitioners may be authorised to supply specified unapproved therapeutic goods to their patients; remove certain offences for persons claiming to be able to arrange supply of therapeutic goods; impose a condition of registration or listing of therapeutic goods; specify the circumstances in which a sponsor may apply for the provisional registration of a medicine, without having to first obtain a provisional determination; introduce a data protection regime for assessed listed medicines; and make minor amendments and corrections; and
    Patents Act 1990
    to remove a reference to therapeutic devices. 

    Bill | Explanatory Memorandum

  • Therapeutic Goods Amendment (2018 Measures No. 1) Bill 2018

    Track (What's this?)

    Date
    28 Jun 2018 
    Chamber
    House of Representatives 
    Status
    Act 
    Portfolio
    Health 
    Summary
    Amends the
    Therapeutic Goods Act 1989
    to: introduce mandatory reporting requirements for sponsors of mainly prescription medicines to report shortages of, and any decision to permanently discontinue, their products; and make miscellaneous amendments in relation to: enabling standards to adopt other documents as in force from time to time; enabling the Secretary to require priority pathway applicants to provide supporting information; streamlining of health practitioner notifications under the Special Access Scheme and certain advertising requirements; variations to registered medicines through notification; and a minor technical amendment. 

    Bill | Explanatory Memorandum

Senator/Member search

Browse all Senators and Members